- Home
- HPK vs ARVN Comparison
HPK vs ARVN Comparison
Compare HPK & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPK
- ARVN
- Stock Information
- Founded
- HPK 2019
- ARVN 2015
- Country
- HPK United States
- ARVN United States
- Employees
- HPK N/A
- ARVN 430
- Industry
- HPK Oil & Gas Production
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- HPK Energy
- ARVN Health Care
- Exchange
- HPK Nasdaq
- ARVN Nasdaq
- Market Cap
- HPK 833.7M
- ARVN 676.2M
- IPO Year
- HPK N/A
- ARVN 2018
- Fundamental
- Price
- HPK $7.02
- ARVN $9.45
- Analyst Decision
- HPK Hold
- ARVN Buy
- Analyst Count
- HPK 3
- ARVN 23
- Target Price
- HPK $11.67
- ARVN $17.61
- AVG Volume (30 Days)
- HPK 450.9K
- ARVN 2.6M
- Earning Date
- HPK 11-05-2025
- ARVN 11-04-2025
- Dividend Yield
- HPK 2.29%
- ARVN N/A
- EPS Growth
- HPK N/A
- ARVN N/A
- EPS
- HPK 0.86
- ARVN N/A
- Revenue
- HPK $964,232,000.00
- ARVN $372,800,000.00
- Revenue This Year
- HPK N/A
- ARVN $1.01
- Revenue Next Year
- HPK N/A
- ARVN N/A
- P/E Ratio
- HPK $8.12
- ARVN N/A
- Revenue Growth
- HPK N/A
- ARVN 299.57
- 52 Week Low
- HPK $6.60
- ARVN $5.90
- 52 Week High
- HPK $15.72
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- HPK 48.41
- ARVN 57.54
- Support Level
- HPK $6.95
- ARVN $9.01
- Resistance Level
- HPK $7.24
- ARVN $9.55
- Average True Range (ATR)
- HPK 0.27
- ARVN 0.49
- MACD
- HPK 0.04
- ARVN -0.10
- Stochastic Oscillator
- HPK 56.94
- ARVN 44.37
About HPK HighPeak Energy Inc.
HighPeak Energy Inc is an independent crude oil and natural gas company focused on the development of unconventional oil and natural gas reserves in Howard County of the Midland Basin. The company operates in a single segment, which is crude oil and natural gas development, exploration, and production in the U.S.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.